最近，创新药行情似乎已经过了“大水漫灌”的阶段，在大额BD、关键临床都带不动整体板块行情的背景之下，对公司的选择也越来越挑剔了。但无论如何演变，市场开始要的总归是那几样东西：数据、现金流（研发持续性），以及确定性。在周期的下半场，没有谁能“躺赢”。今天来盘三家不同的公司，维立志博、德琪和迈威。维立志博绕过了当下主流“冷肿瘤”的技术路径，权力押注了“免疫+”、“TCE+”两大方向；德琪医药在面对核心...
Source Link最近，创新药行情似乎已经过了“大水漫灌”的阶段，在大额BD、关键临床都带不动整体板块行情的背景之下，对公司的选择也越来越挑剔了。但无论如何演变，市场开始要的总归是那几样东西：数据、现金流（研发持续性），以及确定性。在周期的下半场，没有谁能“躺赢”。今天来盘三家不同的公司，维立志博、德琪和迈威。维立志博绕过了当下主流“冷肿瘤”的技术路径，权力押注了“免疫+”、“TCE+”两大方向；德琪医药在面对核心...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.